申请人:AbbVie Inc.
公开号:US20190224220A1
公开(公告)日:2019-07-25
The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
本公开涉及(a)
卡比多巴前药,(b)包括
卡比多巴前药和/或
L-多巴前药的制药组合和组成物,以及(c)治疗帕
金森病及相关疾病的方法,包括向帕
金森病患者施用
卡比多巴前药和
L-多巴前药。